The Boston Examiner
SEE OTHER BRANDS

The most trusted news from Massachusetts

The Boston Examiner: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Boston Examiner.

Press releases published on August 6, 2025

Berkshire Hills Bancorp and Brookline Bancorp to be Combined as Beacon Financial Corporation and Beacon Bank Upon the Closing of their Merger of Equals

Berkshire Hills Bancorp and Brookline Bancorp to be Combined as Beacon Financial Corporation and Beacon Bank Upon the Closing of their Merger of Equals

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Berkshire Hills Bancorp, Inc. (“Berkshire”) (NYSE: BHLB), the parent company of Berkshire Bank, and Brookline Bancorp, Inc. (“Brookline”) (NASDAQ: BRKL), the parent company of Brookline Bank, Bank Rhode Island, and …

Voyager Reports Second Quarter 2025 Financial and Operating Results

Voyager Reports Second Quarter 2025 Financial and Operating Results

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in …

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Keros Therapeutics Reports Second Quarter 2025 Financial Results

LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …

Symbotic Reports Third Quarter Fiscal Year 2025 Results

Symbotic Reports Third Quarter Fiscal Year 2025 Results

WILMINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Symbotic Inc. (Nasdaq: SYM), a leader in A.I.-enabled robotics technology for the supply chain, announced financial results for its third quarter of fiscal year 2025, which ended on June 28, 2025. …

FlossTime Brings Dental Care to Town of Nantucket Employees and a High-Profile Client in Nantucket

FlossTime Brings Dental Care to Town of Nantucket Employees and a High-Profile Client in Nantucket

FlossTime, Boston Dental’s mobile service, provided care to Nantucket staff and made headlines with an exclusive home visit to Barstool President, Dave Portnoy. BOSTON, MA, UNITED STATES, August 6, 2025 /⁨EINPresswire.com⁩/ -- FlossTime, the mobile …

Polymeric Foams Market to Hit $197.8 Billion by 2030

Polymeric Foams Market to Hit $197.8 Billion by 2030

Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Polymeric Foams: Global Markets” is expected to reach $197.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5% from 2025 through 2030. The …

Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029

Global Medical Aesthetic Devices Market to Reach $37.9 Billion by 2029

Boston, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As global demand for aesthetic enhancement rises, medical aesthetic devices are transforming how patients approach cosmetic care. From laser-based treatments to minimally invasive procedures, leading companies such …

Acronis RMM Recognized for Redefining Security-First Automation for MSPs

Acronis RMM Recognized for Redefining Security-First Automation for MSPs

SHAFFHAUSEN, Switzerland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Acronis, a global leader in cybersecurity and data protection, today announced that Acronis RMM (Remote Monitoring and Management) has been selected as the winner in the MSP RMM Platforms category …

COMSOL Announces Keynote Speakers for the COMSOL Conference 2025 Boston

COMSOL Announces Keynote Speakers for the COMSOL Conference 2025 Boston

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- COMSOL, a global leader in modeling and simulation software, announced the keynote speaker lineup for the COMSOL Conference 2025 Boston, which will be held in Boston, MA, on October 8–10. The COMSOL …

CarGurus Honors 2025 Top Dealer Award Winners

CarGurus Honors 2025 Top Dealer Award Winners

The 11th annual program recognizes dealerships raising the bar for customer experience and digital retail innovation BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- CarGurus (Nasdaq: CARG), the No. 1 visited digital auto platform for shopping, buying, and …

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), …

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, …

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today …

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference

CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive …

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics

Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing 2nd lowest redemption rate for a biotech de-SPAC transaction since 2022 BOSTON …

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced …

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44 …

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

– Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO …

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 million Announced FDA acceptance of NDA for new formulation for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions